When Should Skin Pathology Get a Second Opinion?

Direct Answer: Review the Diagnosis When the Decision Is Bigger Than the Certainty

A second opinion is most useful when two conditions are present:

1. Meaningful uncertainty exists, and
2. A different answer would change what happens to the patient.

That second condition is essential. Pathologists can use slightly different words without changing the treatment. A reread is valuable when the disagreement crosses a clinical boundary: benign versus malignant, melanoma in situ versus invasive melanoma, low-grade versus high-grade tumor, superficial versus infiltrative BCC, atypical fibroxanthoma versus pleomorphic dermal sarcoma, or a common lesion versus a rare cancer requiring a different operation.

Most routine skin biopsies do not live on those boundaries. In a blinded review of 589 routine specimens, general pathologists and dermatopathologists agreed in 93.5% of cases; only 1.4% had discrepancies considered potentially important to care.¹ That is reassuring. It also explains why routine rereview is usually low-yield.

The difficult cases are different. Studies from referral centers report much higher change rates because the cases were sent precisely because they were unusual, ambiguous, or treatment-changing.^2–6 Those rates are not the error rate for ordinary pathology. They are evidence that selection matters.

The practical rule is:

“Do not order a second opinion because another opinion feels safer. Order it when the uncertainty and the decision are large enough that another expert view could change the plan.”

- Dr. Hocker

What Is a Dermatopathology Second Opinion?

A dermatopathology second opinion is a new interpretation of existing skin-biopsy material by another qualified physician—usually a board-certified dermatopathologist or a pathologist with focused expertise in the suspected diagnosis.

The reviewer may receive:

• the original glass slides;
• additional unstained slides;
• the paraffin tissue block;
• the original report;
• clinical photographs;
• the exact body site and lesion size;
• the patient's age, symptoms, timeline, and prior treatment;
• the clinician's differential diagnosis and specific question.

The goal is not merely to ask, Do you agree? A useful consultation asks a decision-oriented question:

• Is this melanoma or a severely atypical melanocytic lesion?
• Is invasion present?
• Does the subtype change the surgical margin or margin-control method?
• Is this a low-grade tumor or one with metastatic potential?
• Does the biopsy contain enough tissue to answer the question?
• Would immunostains, molecular testing, deeper sections, or another sample help?

What Actually Happens During the Review?

A second opinion is not simply a second person glancing at the final line of the report.

The receiving laboratory first confirms that the slides and labels match the patient and site. The reviewing pathologist examines the original hematoxylin-and-eosin sections and any prior stains. If the material is adequate, the reviewer develops an independent interpretation and then compares it with the original report and clinical question.

The reviewer may then:

• agree without qualification;
• agree with the diagnosis but refine the subtype, grade, or comment;
• request deeper levels from the block;
• order a focused immunostain panel;
• recommend a validated molecular study;
• ask for clinical photographs or a conversation with the treating dermatologist;
• conclude that the sample is insufficient and recommend another biopsy;
• issue a materially different diagnosis.

The consultation report should explain not only the new label but the practical consequence. Diagnosis changed is less useful than Diagnosis changed from a low-risk lesion to a tumor requiring complete margin assessment.

Why the Reviewer Should Match the Problem

Dermatopathology is a subspecialty, but it contains subspecialties of its own. A physician who reviews high volumes of melanocytic lesions may be the right consultant for a borderline melanoma. A soft-tissue or adnexal-tumor expert may be more useful for a spindle-cell or sweat-gland neoplasm. A cutaneous-lymphoma case may require correlation among dermatopathology, hematopathology, dermatology, and oncology.

The credential is the starting gate, not the finish line. Useful questions include:

• Does the reviewer routinely evaluate this diagnosis?
• Does the laboratory have the ancillary tests the question may require?
• Can the reviewer see the original block and all prior material?
• Is a consensus conference available for a persistent gray-zone case?
• Will the reviewing pathologist speak directly with the treating clinician?

A famous institution is not a substitute for the right expertise and complete information.

First Decide: Is the Problem Interpretation or Sampling?

Patients often assume that any uncertainty can be solved by sending the same slides to a more experienced reader. Sometimes it can. Sometimes the necessary information is not on the slide.

Interpretation uncertainty

The relevant tissue is present, but its meaning is difficult. Examples include:

• an intermediate melanocytic lesion;
• an atypical Spitz tumor;
• a rare adnexal carcinoma;
• a spindle-cell tumor with overlapping features;
• an unusual inflammatory pattern;
• a report using terms such as favor, cannot exclude, or uncertain malignant potential.

Here, expert rereview, consensus conference, immunohistochemistry, or molecular testing may clarify the diagnosis.

Sampling uncertainty

The biopsy may not contain the part of the lesion that would answer the question. Examples include:

• a superficial sample of a deeper tumor;
• a small punch from a large mixed lesion;
• a specimen transected at the base when depth changes the decision;
• melanoma in situ on biopsy with concern for an invasive focus elsewhere;
• BCC whose aggressive component lies outside the sampled area;
• a spindle-cell tumor that cannot be classified because the biopsy does not reach the subcutaneous tissue.

Another reader cannot see tissue that was never sampled. The answer may require deeper sections from the block, additional tissue from the same lesion, or definitive removal.^21–23

Think of it this way: rereading a photograph can clarify what is visible in the frame. It cannot show what was outside the frame when the photograph was taken.

When Should You Consider Expert Review?

1. The report uses genuinely uncertain language

Phrases such as these should trigger a question about what remains unresolved:

• atypical melanocytic proliferation;
• melanocytic tumor of uncertain malignant potential;
• cannot exclude melanoma;
• suspicious for malignancy;
• favor benign or favor malignant;
• differential includes both a benign lesion and a cancer;
• additional studies pending;

These phrases do not all carry the same probability, and pathologists and clinicians do not always interpret them identically.^7–9 The patient should not try to convert them into a home percentage. The useful question is: What uncertainty is the phrase communicating, and what decision depends on resolving it?

2. The pathology and the clinical appearance do not agree

The microscope is a close-up. The dermatologist's examination supplies the landscape.

If a lesion looks and behaves like an invasive tumor but the report describes a harmless superficial process, the mismatch matters. The reverse also matters: a result suggesting an aggressive malignancy deserves correlation if the site, appearance, and history are strikingly inconsistent.

Clinical context can improve interpretation. Reviews and diagnostic studies support providing the exact site, lesion morphology, photographs, and clinician's differential diagnosis, particularly for melanocytic and inflammatory lesions.^10–12

Clinicopathologic correlation can lead to several reasonable outcomes:

• the diagnosis is confirmed after context is added;
• the pathologist issues an addendum;
• deeper sections or stains are ordered;
• expert review is requested;
• a new biopsy targets the area that best explains the clinical concern.

3. The diagnosis is an intermediate melanocytic lesion

Melanocytic pathology has a well-documented gray zone. In the M-Path study, experienced pathologists performed well at the clearly benign end of the spectrum, but accuracy and reproducibility were much lower for intermediate lesions and melanoma in situ.¹³

This does not mean melanoma is usually misdiagnosed. The histologic features used to separate benign, intermediate, in situ, and invasive melanocytic lesions can overlap, so qualified pathologists do not always classify the same specimen the same way. When a report sits near a boundary that changes excision, staging, or follow-up, expert review is reasonable.

Second-opinion strategies improve diagnostic accuracy, but reviewing every melanocytic biopsy is not the best strategy. Decision modeling supports selective review—targeting the uncertain and treatment-changing cases—rather than universal rereview.¹⁴

4. The tumor is rare

Rare tumors are encountered less often, so review by a pathologist with diagnosis-specific experience can add value.

Expert review is especially reasonable for:

• dermatofibrosarcoma protuberans (DFSP);
• sebaceous carcinoma or a difficult sebaceous neoplasm;
• atypical fibroxanthoma versus pleomorphic dermal sarcoma;
• microcystic adnexal carcinoma and other adnexal cancers;
• sweat-gland carcinoma;
• extramammary Paget disease;
• Merkel cell carcinoma;
• cutaneous lymphoma;
• unusual spindle-cell or soft-tissue tumors.

The French CARADERM network reviewed 2,573 suspected skin adnexal carcinoma cases and changed the diagnosis in 21.3% after expert review, including a change across the benign-versus-malignant boundary in 5%.¹⁵ Diagnostic change occurred in 45.7% of provisional referrals versus 2.8% of already established diagnoses. Those numbers apply to a rare-tumor expert network, not routine biopsies. They show why rare cancer and diagnostic uncertainty are reasonable places to spend expert attention.

5. The diagnosis changes the operation or staging

Review deserves priority before an irreversible step when a revised diagnosis would change:

• whether surgery is needed at all;
• Mohs versus standard excision versus another operation;
• margin width or use of complete mapped margin assessment;
• sentinel lymph node biopsy discussion;
• imaging or nodal evaluation;
• radiation or systemic therapy;
• reconstruction timing;
• follow-up intensity.

A UCSF cohort of 358 selected malignant referrals found diagnostic disagreement in 10.3% and a change in surgical management in 8.9%.³ Of the 32 management changes, 28 were cancellations of planned surgery. The cohort was selected and should not be generalized to all skin cancers. It shows why review is most valuable when an irreversible operation depends on a genuinely uncertain diagnosis.

6. The tumor behaves more aggressively than the report predicts

Rapid recurrence, unexpected spread, nerve symptoms, unusually fast growth, or metastasis should prompt the team to revisit both the clinical plan and the original diagnosis. The possibilities include:

• an under-sampled aggressive component;
• an incorrect subtype;
• a rare mimic;
• a collision tumor;
• transformation within a previously lower-grade lesion;
• correct pathology but biology more aggressive than average.

A second opinion is not the only response. The team may need a new biopsy, imaging, additional staging, or multidisciplinary review.

When Is a Second Opinion Usually Unnecessary?

Additional review usually adds little when all of the following are true:

• the diagnosis is common and stated confidently;
• the pathology fits the clinical appearance;
• the sample is adequate for the question;
• no rare or treatment-changing subtype is suspected;
• the treating dermatologist and pathologist agree on the implication;
• another interpretation would not change treatment.

Examples might include a classic seborrheic keratosis, a straightforward epidermoid cyst, or a routine BCC whose subtype, location, and treatment plan are clear.

Second opinions have costs beyond money. Slide transfer can delay treatment, and additional interpretations can create noise rather than clarity. The purpose is not to collect votes. It is to improve the decision.

Why More Opinions Is Not the Same as More Certainty

If three pathologists use three labels, obtaining a fourth label may not solve the case. The team must identify why the labels differ.

Common reasons include:

• a true biological gray zone;
• different diagnostic thresholds;
• inadequate tissue;
• different sections showing different parts of a mixed lesion;
• missing clinical information;
• an ancillary test with imperfect specificity;
• simple interpretive error.

Each problem has a different remedy. A threshold problem may benefit from consensus. A tissue problem needs more tissue. A context problem needs photographs and history. A test problem requires understanding the assay rather than treating it as a vote.

The patient's goal is not unanimous language at any cost. It is a diagnosis reliable enough to support a safe plan.

When Does Another Test Help More Than Another Reader?

Ancillary tests are not truth machines. Immunostains and molecular assays have their own false positives, false negatives, and interpretation problems. Professional appropriate-use criteria support selecting tests for a defined diagnostic question rather than ordering a large panel because uncertainty feels uncomfortable.¹⁶

What Materials Should Be Sent?

The receiving dermatopathologist should ideally have:

1. the complete original report and any addenda;
2. all representative slides, not only one selected slide;
3. the tissue block or unstained slides when additional testing may be needed;
4. the exact biopsy site and laterality;
5. clinical photographs or dermoscopic images when available;
6. lesion size, duration, symptoms, and change over time;
7. prior biopsies, excisions, radiation, or treatment at the site;
8. the clinician's differential diagnosis;
9. the decision the review must inform.

The last item turns a generic reread into a useful consultation.

What Can the Second Opinion Conclude?

The result is not limited to agree or disagree.

Confirmed diagnosis

The reviewer agrees with the original diagnosis. This can be valuable when the operation is major or the diagnosis is rare.

Clarified terminology

The reviewer may preserve the diagnosis but refine the subtype, grade, depth, or uncertainty.

Changed diagnosis

The lesion may move across a clinically important boundary, such as benign to malignant, in situ to invasive, or AFX to pleomorphic dermal sarcoma.

Additional testing recommended

Deeper sections, immunostains, molecular testing, or comparison with prior material may be needed.^16,17

More tissue needed

The most honest answer can be that the existing biopsy is insufficient. A new biopsy is not a failure of review; it is recognition that the missing information is physical tissue, not interpretation.

What If Two Experts Still Disagree?

Persistent disagreement is uncomfortable, but it is not proof that one person is careless. Some lesions exist at microscopic boundaries where the available criteria do not produce perfect reproducibility.^13,24

When disagreement remains:

1. identify the exact point of disagreement;
2. determine whether it changes management;
3. review clinical photographs and the full specimen;
4. consider consensus conference;
5. use ancillary testing only if it is validated for that question;
6. obtain more tissue when sampling is the limitation;
7. choose a management plan that is safe under the remaining uncertainty.

Sometimes the report should preserve uncertainty rather than manufacture false confidence. The treating team can then make a transparent decision with the patient.

Decision Table: Consider Review or Usually Proceed?

Four Examples

Example 1: A routine nodular BCC that fits the examination

The report is confident, the dermatologist agrees with it, and the planned treatment would not change after another reading. External review is unlikely to add value.

Example 2: Atypical melanocytic proliferation; cannot exclude melanoma in situ

The report straddles a boundary that could change whether observation or surgery is recommended. Expert melanocytic review, complete clinical information, and possibly additional testing are reasonable before treatment.

Example 3: A spindle-cell tumor on a partial superficial biopsy

The pathologist lists AFX, pleomorphic dermal sarcoma, and another sarcoma. The distinction depends partly on depth and invasion into subcutaneous tissue. A reread may help, but the existing sample may not contain the feature required to classify the lesion. More tissue is likely part of the answer.

Example 4: A rare adnexal carcinoma before a major facial operation

The diagnosis is uncommon, and a different classification could change the margin method, staging, or need for multidisciplinary care. Expert review before irreversible treatment has a high potential value.¹⁵

How to Request Review Without Losing Momentum

1. Tell the treating physician why review is being considered.
2. Identify the reviewer or institution before requesting shipment.
3. Ask which materials the reviewer needs.
4. Confirm whether the original laboratory or the patient must sign a release.
5. Ask whether treatment should continue, pause, or be tentatively scheduled while review is pending.
6. Confirm who will reconcile the two reports and explain the final plan.

Avoid leaving the patient between two laboratories with no physician responsible for the decision. A report is information; clinical ownership still matters.

Questions Patients Can Ask

• Is the diagnosis stated confidently, or is meaningful uncertainty present?
• Does the pathology match what the lesion looked and felt like?
• Would a different diagnosis change surgery, margin, staging, or follow-up?
• Is the problem interpretation, or might the biopsy have missed the key area?
• Should the slides be reviewed by a board-certified dermatopathologist with experience in this diagnosis?
• Does the reviewer need photographs, the original block, or all prior specimens?
• Would deeper sections, immunostains, molecular testing, or another biopsy answer the question better?
• Can treatment proceed safely while review is pending?

Next Steps in the Patient Journey

• First translate the original report with What Does My Skin Biopsy Report Mean?
• If sampling may be the problem, review What Is a Skin Biopsy and What Should I Expect?
• If the diagnosis is settled, continue to I Was Diagnosed With Skin Cancer. What Happens Next?
• Use Low-Risk vs High-Risk Skin Cancer to understand which features change treatment intensity.
• Move to the diagnosis-specific BCC, cSCC, melanoma, or rare-tumor pathway.

Ask the treating dermatologist one decisive question: Would another interpretation change what you recommend? If the answer is yes, review should occur before the irreversible decision whenever the clinical situation permits.